An evaluation of the International Diabetes Federation definition of metabolic syndrome in Chinese patients older than 30 years and diagnosed with type 2 diabetes mellitus

被引:59
作者
Lu, Bin
Yang, Yehong
Song, Xiaoyan
Dong, Xuehong
Zhang, Zhaoyun
Zhou, Linuo
Li, Yiming
Zhao, Naiqing
Zhu, XiXing
Hu, Renming [1 ]
机构
[1] HuaShan Hosp, Dept Endocrinol & Metab, Shanghai 200040, Peoples R China
[2] Fudan Univ, Inst Endocrinol & Diabetol, Shanghai 200032, Peoples R China
[3] Fudan Univ, Dept Publ Hlth Sci, Shanghai 200032, Peoples R China
来源
METABOLISM-CLINICAL AND EXPERIMENTAL | 2006年 / 55卷 / 08期
基金
中国国家自然科学基金;
关键词
D O I
10.1016/j.metabol.2006.04.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The objective of the study was to determine the most accurate metabolic syndrome (MS) definition among the definitions proposed by the International Diabetes Federation (IDF), the Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III [ATPIII]), and the World Health Organization (WHO) and to evaluate the cutoff point of waist circumference using the IDF definition for optimally defining MS in the Chinese population. One thousand thirty-nine Chinese patients older than 30 years and diagnosed with type 2 diabetes mellitus were investigated by randomized cluster sampling in the Shanghai downtown, and 1008 patients were analyzed in this study. Body mass measurements, resting blood pressure, fasting blood measures, and carotid atherosclerotic measurements including common carotid artery intima-media thickness (IMT) and carotid plaque were investigated. The IDF definition was compared with the other 2 definitions, and the carotid atherosclerosis was evaluated among the patients according to these definitions. (1) The MS prevalence was 50.0%, 55.7%, and 70.0% under the IDF, ATPIII, and WHO definitions, respectively. (2) The percentage of all the participants categorized as either having or not having the MS was 69.9% (under the IDF and ATPIII definitions) and 70.2% (under the IDF and WHO definitions). (3) Common carotid artery IMT of patients with MS determined by the IDF definition was thicker than those determined by the WHO and ATPIII definitions, and the percentage of carotid plaque of patients with MS determined by the IDF definition was greater than those determined by the WHO and ATPIII definitions. (4) When the cutoff point of waist circumference in men determined by the IDF definition was modified from 90 to 85 cm, common carotid artery IMT of the emerging male patients with MS was thicker than that of the male patients with MS determined by the original IDF definition. In conclusion, the prevalence of MS was 50.0%, 55.7%, and 70.0% under the IDF, ATPIII, and WHO definitions, respectively. The preferable IDF definition served as a better predictor of cardiovascular disease risk in the Chinese patients diagnosed with type 2 diabetes mellitus compared with the ATPIII and WHO definitions. The modified cutoff point of waist circumference in men under the IDF definition specific for the Chinese population (from 90 to 85 cm) might be more suitable for predicting atherosclerosis. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:1088 / 1096
页数:9
相关论文
共 46 条
[1]  
Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO
[2]  
2-S
[3]  
Alebiosu CO, 2004, J NATL MED ASSOC, V96, P817
[4]  
[Anonymous], 2000, ASIA PACIFIC PERSPEC
[5]  
[Anonymous], 2004, DIABETES CARE, DOI DOI 10.2337/DIACARE.27.5.1240-A
[6]   Discrimination of health risk by combined body mass index and waist circumference [J].
Ardern, CL ;
Katzmarzyk, PT ;
Janssen, I ;
Ross, R .
OBESITY RESEARCH, 2003, 11 (01) :135-142
[7]   Common carotid intima-media thickness and risk of stroke and myocardial infarction - The Rotterdam Study [J].
Bots, ML ;
Hoes, AW ;
Koudstaal, PJ ;
Hofman, A ;
Grobbee, DE .
CIRCULATION, 1997, 96 (05) :1432-1437
[8]   Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 3 diabetes [J].
Bruno, G ;
Merletti, F ;
Biggeri, A ;
Bargero, G ;
Ferrero, S ;
Runzo, C ;
Cerai, SP ;
Pagano, G ;
Cavallo-Perin, P .
DIABETES CARE, 2004, 27 (11) :2689-2694
[9]  
Chambless LE, 1997, AM J EPIDEMIOL, V146, P483, DOI 10.1093/oxfordjournals.aje.a009302
[10]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497